Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06008860 · ClinicalTrials.gov registry record · Phase 4
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
A Phase 4 study of COVID-19, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 280
- Enrollment target
- 1
- Study location
NCT06008860: Recruiting Phase 4 study of COVID-19, sponsored by University of Chicago.
NCT06008860 is a Phase 4 study of COVID-19 that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 280 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06008860, a Phase 4 study of COVID-19, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 280 participants
- Enrollment target
- 1
- Study location
Study Summary
The study team proposes to evaluate the efficacy of Astepro® 0.15% nasal spray in treating SARS-CoV-2 infection in adults through a pilot and feasibility clinical trial at the University of Chicago.
Primary Outcome
The primary cohort will be followed while utilizing study drug or placebo to evaluate the outcomes and saliva collection to follow viral load.
Conditions Studied
Interventions
- DRUG Experimental: Primary Cohort
- OTHER Placebo Comparator: Primary Cohort - Placebo
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
What NCT06008860 shows while recruiting
NCT06008860 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Experimental: Primary Cohort is the first listed.
NCT06008860 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06008860 about?
NCT06008860 is a clinical study titled "A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection". The study team proposes to evaluate the efficacy of Astepro® 0.15% nasal spray in treating SARS-CoV-2 infection in adults through a pilot and feasibility clinical trial at the University of Chicago.
What is the current status of trial NCT06008860?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 280 participants. The study started on 2023-07-01. Estimated completion is 2026-12.
What conditions does trial NCT06008860 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT06008860?
The interventions under investigation include: Experimental: Primary Cohort (DRUG), Placebo Comparator: Primary Cohort - Placebo (OTHER).
Who is sponsoring clinical trial NCT06008860?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06008860 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06008860's enrollment target sits among peer trials
280 146th of 298 higher than 153 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
RECRUITING · Phase 4
-
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
COVID-19 Reactogenicity
ACTIVE NOT RECRUITING · Phase 4
-
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
ACTIVE NOT RECRUITING · Phase 4
-
Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI